🚀 go-pugleaf

Dernières parutions d'articles librement accessibles concernant le
cancer du sein triple-négatif:
Most recent free articles on triple-negative breast cancer:


Breast cancer stem-like cells are inhibited by a non-toxic aryl
hydrocarbon receptor agonist.
Prud'homme GJ, Glinka Y, Toulina A, Ace O, Subramaniam V, Jothy S.
PLoS One. 2010 Nov 3;5(11):e13831.
http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0013831


Triple-negative breast cancer.
Chacón RD, Costanzo MV.
Breast Cancer Res. 2010;12 Suppl 2:S3.
http://breast-cancer-research.com/content/12/S2/S3/?mkt=


Treatment Options for Patients with Triple-Negative Breast Cancer.
Santana-Davila R, Perez EA.
J Hematol Oncol. 2010 Oct 27;3(1):42.
http://www.jhoonline.org/content/3/1/42


Triple negativity and young age as prognostic factors in lymph node-
negative invasive ductal carcinoma of 1 cm or less.
Kwon JH, Kim YJ, Lee KW, Oh DY, Park SY, Kim JH, Chie EK, Kim SW, Im
SA, Kim IA, Kim TY, Park IA, Noh DY, Bang YJ, Ha SW.
BMC Cancer. 2010 Oct 15;10:557.
http://www.biomedcentral.com/1471-2407/10/557


Hydrophobic Proteome Analysis of Triple Negative and Hormone-Receptor-
Positive-Her2-Negative Breast Cancer by Mass Spectrometer.
Lu M, Whelan SA, He J, Saxton RE, Faull KF, Whitelegge JP, Chang HR.
Clin Proteomics. 2010 Sep;6(3):93-103.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2937135/?tool=pubmed


Favorable response to doxorubicin combination chemotherapy does not
yield good clinical outcome in patients with metastatic breast cancer
with triple-negative phenotype.
Yi SY, Ahn JS, Uhm JE, Lim do H, Ji SH, Jun HJ, Kim KH, Chang MH, Park
MJ, Cho EY, Choi YL, Park YH, Im YH.
BMC Cancer. 2010 Oct 5;10:527.
http://www.biomedcentral.com/1471-2407/10/527


Triple-negative, basal-like, and quintuple-negative breast cancers:
better prediction model for survival.
Choi YL, Oh E, Park S, Kim Y, Park YH, Song K, Cho EY, Hong YC, Choi
JS, Lee JE, Kim JH, Nam SJ, Im YH, Yang JH, Shin YK.
BMC Cancer. 2010 Sep 23;10:507.
http://www.biomedcentral.com/1471-2407/10/507


Molecular biomarker analyses using circulating tumor cells.
Punnoose EA, Atwal SK, Spoerke JM, Savage H, Pandita A, Yeh RF,
Pirzkall A, Fine BM, Amler LC, Chen DS, Lackner MR.
PLoS One. 2010 Sep 8;5(9):e12517.
http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0012517


Overexpression of the RNA binding protein HuR impairs tumor growth in
triple negative breast cancer associated with deficient angiogenesis.
Gubin MM, Calaluce R, Davis JW, Magee JD, Strouse CS, Shaw DP, Ma L,
Brown A, Hoffman T, Rold TL, Atasoy U.
Cell Cycle. 2010 Aug 15;9(16):3337-46.
http://www.landesbioscience.com/journals/cc/article/GubinCC9-16.pdf
















InTextoResearch, Baelen, Liège, Belgique (Belgium) & OncoWal/Wallogene
(Marc Lacroix , scimedweb@mail.com)